https://orcid.org/0000-0002-2549-644X
References
- Gaulard P, Swerdlow SH, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon (France): IARC; 2017. p. 462–464.
- Hellgren K, Baecklund E, Backlin C, et al. Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased? Arthritis Rheumatol. 2017;69(4):700–708.
- Yamada T, Nakajima A, Inoue E, et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int. 2011;31(11):1487–1492.
- Hashimoto A, Chiba N, Tsuno H, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42(4):564–571.
- Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70(11):1895–1904.
- Wong AK, Kerkoutian S, Said J, et al. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol. 2012;31(4):631–636.
- Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898–908.
- Willemze R, Vergier B, Duncan LM. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon (France): IARC; 2017. p. 303–304.
- Calip GS, Patel PR, Adimadhyam S, et al. Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. Int J Cancer. 2018;143(5):1062–1071.
- Kurita D, Miyoshi H, Ichikawa A, et al. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors. Am J Surg Pathol. 2019;43(7):869–884.
- Flynn AD, Azar JM, Chiorean MV. Spontaneous regression of colonic lymphoma following infliximab and azathioprine withdrawal in patients with Crohn’s disease. Inflamm Bowel Dis. 2013;19:E69–E70.
- Cassaday RD, Malik JT, Chang JE. Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn’s disease: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2011;11(3):289–292.
- Tokuhira M, Tamaru JI, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop. 2019;59(2):72–92.
- Inui Y, Matsuoka H, Yakushijin K, et al. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma. 2015;56(11):3045–3051.
- Tokuhira M, Tanaka Y, Takahashi Y, et al. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders . J Clin Exp Hematop. 2020;60(2):41–50.
- Momose S, Tamaru J. Iatrogenic immunodeficiency-associated lymphoproliferative disorders of B-cell type that develop in patients receiving immunosuppressive drugs other than in the post-transplant setting. J Clin Exp Hematop. 2019;59(2):48–55.
- Mercer LK, Regierer AC, Mariette X, et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis. 2017;76(12):2025–2030.
- Matsumoto Y, Horiike S, Maekawa S, et al. Rheumatoid arthritis/methotrexate-associated primary cutaneous diffuse large B-cell lymphoma, leg type. Intern Med. 2014;53(11):1177–1181.
- Gaulard P, Swerdlow SH, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon (France): IARC; 2017. p. 307–308.
- Hope CB, Pincus LB. Primary cutaneous B-cell lymphomas. Clin Lab Med. 2017;37(3):547–574.
- Niitsu N, Okamoto M, Nakamine H, et al. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci. 2010;101(5):1309–1313.
- Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol. 2006;24(9):1376–1382.
- Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007;25(12):1581–1587.